ZHONG JI LS (00767) announced on December 1, 2025, that the company intends to acquire a 25% stake in Asia Integrated Cell Bank Limited from China International Bone & Joint Medical Group for an initial consideration of HK$300 million. The payment will be settled by issuing non-redeemable convertible notes up to HK$300 million under a special mandate.

The target company operates a premium customized stem cell and iPSC storage center, providing testing and preclinical immunotherapy services to clients across multiple regions, particularly high-net-worth individuals in Hong Kong and mainland China. It also operates under the trade names "Wesman Academician International Advanced Medical Center" and "Asia International Medical Testing Center," with a professional team of registered doctors and laboratory technicians delivering auxiliary medical services.

The board believes that stem cell and iPSC storage services, along with cellular immunotherapy, represent high-growth potential sectors. Cellular immunotherapy, in particular, is experiencing exponential growth driven by rising consumer demand and increasing investments in advanced skin regeneration, vitality enhancement, comprehensive wellness solutions, preclinical intervention strategies, and proactive health management.